For years, the Mexican clinical research industry has expressed its wish to grow internationally and to rival countries like Brazil and Costa Rica. In early 2017, an agreement was reached to begin performing clinical trials within the IMSS, which is widely expected to boost investment in the sector. COFEPRIS hopes to triple the US$200 million invested annually in this sector in Mexico by 2019 and the year 2018 will be key to achieving this goal. As of mid-2017, Mexico performed only 1 percent of the world’s clinical trials, dwarfed by its neighbor the US that performed 41 percent.
This chapter will showcase the developments that take place through interviews with the most relevant sector players and highlight what steps they are taking to increase investment in the sector.
-> Why is developing clinical research activities in Mexico important? How are you working to increase investment in clinical research in Mexico and which partnerships will be key?